Cargando…
Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor
Protein kinase CK2 is involved in regulating cellular processes, such as cell cycle, proliferation, migration, and apoptosis, making it an attractive anticancer target. We previously described a prenyloxy-substituted indeno[1,2-b]indole (5-isopropyl-4-(3-methylbut-2-enyloxy)-5,6,7,8-tetrahydroindeno...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226678/ https://www.ncbi.nlm.nih.gov/pubmed/34198928 http://dx.doi.org/10.3390/ph14060542 |
_version_ | 1783712344079073280 |
---|---|
author | El-Awaad, Ehab Birus, Robin Marminon, Christelle Bouaziz, Zouhair Ballentin, Laurens Aichele, Dagmar Le Borgne, Marc Jose, Joachim |
author_facet | El-Awaad, Ehab Birus, Robin Marminon, Christelle Bouaziz, Zouhair Ballentin, Laurens Aichele, Dagmar Le Borgne, Marc Jose, Joachim |
author_sort | El-Awaad, Ehab |
collection | PubMed |
description | Protein kinase CK2 is involved in regulating cellular processes, such as cell cycle, proliferation, migration, and apoptosis, making it an attractive anticancer target. We previously described a prenyloxy-substituted indeno[1,2-b]indole (5-isopropyl-4-(3-methylbut-2-enyloxy)-5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-dione (4p)) as a very potent inhibitor of CK2 holoenzyme (IC(50) = 25 nM). Here, we report the broad-spectrum anticancer activity of 4p and provide substantial progress on its pharmacokinetic properties. Using a cell-based CK2 activity assay and live-cell imaging of cultured A431, A549, and LNCaP cancer cell lines, cellular CK2 target engagement was shown as well as strong antiproliferative, anti-migratory and apoptosis-inducing effects of 4p. Furthermore, evidence was found for the ability of 4p to disrupt A549 spheroid cohesion. A series of LC-MS/MS experiments revealed high and rapid cellular uptake (intracellular concentration is approximately 5 µM after 1 h incubation) and low metabolic stability of 4p. These results point to the value of 4p as a potent CK2 inhibitor with promising anticancer activities and should trigger future medicinal chemistry efforts to improve the drug-like properties of this compound. |
format | Online Article Text |
id | pubmed-8226678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82266782021-06-26 Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor El-Awaad, Ehab Birus, Robin Marminon, Christelle Bouaziz, Zouhair Ballentin, Laurens Aichele, Dagmar Le Borgne, Marc Jose, Joachim Pharmaceuticals (Basel) Article Protein kinase CK2 is involved in regulating cellular processes, such as cell cycle, proliferation, migration, and apoptosis, making it an attractive anticancer target. We previously described a prenyloxy-substituted indeno[1,2-b]indole (5-isopropyl-4-(3-methylbut-2-enyloxy)-5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-dione (4p)) as a very potent inhibitor of CK2 holoenzyme (IC(50) = 25 nM). Here, we report the broad-spectrum anticancer activity of 4p and provide substantial progress on its pharmacokinetic properties. Using a cell-based CK2 activity assay and live-cell imaging of cultured A431, A549, and LNCaP cancer cell lines, cellular CK2 target engagement was shown as well as strong antiproliferative, anti-migratory and apoptosis-inducing effects of 4p. Furthermore, evidence was found for the ability of 4p to disrupt A549 spheroid cohesion. A series of LC-MS/MS experiments revealed high and rapid cellular uptake (intracellular concentration is approximately 5 µM after 1 h incubation) and low metabolic stability of 4p. These results point to the value of 4p as a potent CK2 inhibitor with promising anticancer activities and should trigger future medicinal chemistry efforts to improve the drug-like properties of this compound. MDPI 2021-06-05 /pmc/articles/PMC8226678/ /pubmed/34198928 http://dx.doi.org/10.3390/ph14060542 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article El-Awaad, Ehab Birus, Robin Marminon, Christelle Bouaziz, Zouhair Ballentin, Laurens Aichele, Dagmar Le Borgne, Marc Jose, Joachim Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor |
title | Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor |
title_full | Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor |
title_fullStr | Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor |
title_full_unstemmed | Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor |
title_short | Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor |
title_sort | broad-spectrum anticancer activity and pharmacokinetic properties of a prenyloxy-substituted indeno[1,2-b]indole derivative, discovered as ck2 inhibitor |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226678/ https://www.ncbi.nlm.nih.gov/pubmed/34198928 http://dx.doi.org/10.3390/ph14060542 |
work_keys_str_mv | AT elawaadehab broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor AT birusrobin broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor AT marminonchristelle broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor AT bouazizzouhair broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor AT ballentinlaurens broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor AT aicheledagmar broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor AT leborgnemarc broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor AT josejoachim broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor |